Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesNeuroThera Labs Inc.

NeuroThera Labs Inc.

Healthcare Drug Manufacturers - General
PortfolioPortfolio WatchlistWatchlist
Company price
1.61 CAD 0.00(0%)
Last update at 2026-11-06T14:30:00Z
Market Cap
13.50M

Momentum Score

…

Neurothera Labs Inc. operates a clinical-stage pharmaceutical company. The company engages in the drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. Neurothera Labs Inc. was formerly known as Miza III Ventures Inc. The company is based in Vancouver, Canada. As of February 23, 2023, Neurothera Labs Inc. operates as a subsidiary of SciSparc Ltd.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.61
Low
1.61
High
52 Week Price Range
0.15
Low
0.26
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

NeuroThera Labs Inc. (NTLX.V) is a small-cap company listed on the TSX Venture Exchange with limited public disclosure about its operations. Long-term growth appears to depend on successful clinical or product development, regulatory approvals, and partnerships or licensing that could enable commercialization. Investors may find upside if scientific validation and commercial milestones are achieved.

Principal risks are limited disclosure and liquidity, dependence on external financing, early-stage development and the high probability of regulatory or clinical setbacks.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.61
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-
Net Debt
-
ROCE
-27.62%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-01-31 2024-01-31 2023-01-31 2022-01-31
Type yearly yearly yearly yearly
Date 2025-01-31 2024-01-31 2023-01-31 2022-01-31
Income before tax -0.26M -0.10M -0.08M -0.15M
Net income -0.26M -0.10M -0.08M -0.15M
Selling general administrative 0.23M 0.09M 0.07M 0.11M
Operating income -0.26M -0.10M -0.08M -0.15M
Net interest income -0.00M -0.00M -0.00M -0.00M
Total revenue 0.00M 0.00M 0.00M 0.00M
Total operating expenses 0.26M 0.10M 0.08M 0.15M
Net income from continuing ops -0.26M -0.10M -0.08M -0.15M
Breakdown 2025-01-31 2024-01-31 2023-01-31 2022-01-31
Type yearly yearly yearly yearly
Date 2025-01-31 2024-01-31 2023-01-31 2022-01-31
Total assets 1.08M 1.22M 1.28M 1.37M
Total liab 0.16M 0.04M 0.01M 0.02M
Total stockholder equity 0.92M 1.18M 1.27M 1.35M
Capital stock 1.48M 1.48M 1.47M 1.47M
Retained earnings -0.60M -0.34M -0.24M -0.16M
Cash 1.08M 1.22M 1.28M 1.36M
Total current liabilities 0.16M 0.04M 0.01M 0.02M
Total current assets 1.08M 1.22M 1.28M 1.37M
Accounts payable 0.01M 0.02M - -
Non current assets total 0.00M 0.00M 0.00M 0.00M
Breakdown 2025-01-31 2024-01-31 2023-01-31 2022-01-31
Type yearly yearly yearly yearly
Date 2025-01-31 2024-01-31 2023-01-31 2022-01-31
Total cash from financing activities 0.00M 0.01M 0.00M 1.33M
Net income -0.26M -0.10M -0.08M -0.15M
Change in cash -0.14M -0.06M -0.08M 1.22M
Begin period cash flow 1.22M 1.28M 1.36M 0.14M
End period cash flow 1.08M 1.22M 1.28M 1.36M
Total cash from operating activities -0.14M -0.07M -0.08M -0.11M
Issuance of capital stock - - 0.00M 1.33M
Capital expenditures 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.11M 0.03M -0.00M 0.01M
Stock based compensation - - 0.00M 0.04M
Free cash flow -0.14M -0.07M -0.08M -0.11M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - General

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NTLX
NeuroThera Labs Inc.		 -
-%		 1.61 - - - 15.14 -12.29

Profile*

NeuroThera Labs Inc.

Neurothera Labs Inc. operates a clinical-stage pharmaceutical company. The company engages in the drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. Neurothera Labs Inc. was formerly known as Miza III Ventures Inc. The company is based in Vancouver, Canada. As of February 23, 2023, Neurothera Labs Inc. operates as a subsidiary of SciSparc Ltd.

, Vancouver, BC, Canada

https://www.neurothera.com

Name Title Year Born
Mr. Oz Adler CPA Chief Executive Officer 1987
Mr. Gabriel Kabazo CFO & Corporate Secretary 1974
Michal Efraty IR Manager NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…